Aurora Cannabis launches its first range of German-grown medical cannabis products

Aurora Cannabis has officially launched its first brand of home-grown medical cannabis, IndiMed.

A new product for the German market

The brand's first offering IndiMed is the sativa variety Island Sweet Skunk, a cannabis flower containing 20% of THC and less 1 % of CBD. Known for its grapefruit and citrus notes, this variety is grown at Aurora's state-of-the-art, EU-GMP-certified facilities in Leuna, Germany.

This installation obviously adheres to the Good Agricultural and Collection Practices (GACP) and good manufacturing practice (GMP) from the EU, which guarantee the pharmaceutical quality of medical cannabis products.

Michael Simon, Interim President of Aurora Europe, noted the significance of the launch, saying: «Aurora is proud to offer its first locally manufactured medical cannabis product to the growing German market, an important milestone since Germany has decided to legalize cannabis in April 2024. »

Aurora's expansion in Europe

Aurora Cannabis has steadily built up its presence in Europe over the past decade, starting with the’acquisition of Pedanios in Germany in 2017. The company then supplied its products to Italy, France, the Nordic countries and Poland, adapting to strict regulations and investing in research and development.

Aurora's Leuna facility, which has been operational for four years, produces around 1,000 kilograms of medical cannabis a year and received expanded cultivation and research licenses last summer.

The German subsidiary, Aurora Europe GmbH, is one of the world's leading only three licensed medical cannabis growers in the country. The other two operators are Demecan GmbH and Aphria, a subsidiary of Tilray Brands Inc.

The German medical cannabis market has grown significantly since the country legalized medical cannabis in 2017. Recent legislative changes in 2024, including the decriminalization of recreational cannabis, have made access even easier for patients.

The German medical cannabis market has generated more than 450 million in revenues last year, and analysts at Prohibition Partners forecast that this figure could exceed billion by the end of the decade. Sales of medical cannabinoid products increased by 3% year-on-year in the third quarter of 2024, pointing to solid future growth.

In addition, the number of patients using medical cannabis in Germany should increase considerably, as access was made easier last April.

Aurora is not alone in capitalizing on Germany's burgeoning cannabis market. Other Canadian companies, including High Tide Inc. and Organigram Holdings Inc. have also invested in this sector. High Tide, for example, recently acquired a 51%'s stake in Frankfurt-based Purecan GmbH, reinforcing Canada's presence in the European market.